Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Do fetuses perceive social stimuli? A magnetoencephalography investigation of the prenatal mind. (FETAL-MIND)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The Human Mind and Its Compl exity
Panel description: Cognitive science, psychology, linguistics
Countries involved: Germany
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-02-01
End date: 2031-01-31
Duration (months): 60.0
Total project cost (EUR): 1499695.0
EU funding (EUR): 1499695.0
Participants: 1
Project status: SIGNED

What can a fetus perceive? Leveraging rare, specialized resources at the University of Tuebingen's fMEG Center, FETAL-MIND will conduct the first-ever study of fetal neural responses to social stimuli using recent innovations toward in utero stimulus delivery and cutting edge techniques for fetal brain signal detection. This groundbreaking project will challenge the widespread view of fetuses as isolated and unaware by examining fetal neural responses to non-maternal vocal stimuli and face-like patterns projected into the womb. Specifically, FETAL-MIND will use fetal magnetoencephalography (MEG) in the third trimester (32-40 weeks gestation), employing both traditional superconducting MEG (sMEG) and newer optically pumped magnetometers (oMEG) to detect fetal neural responses to social stimuli (face-like patterns and voices). Compared with sMEG, oMEG is portable, less expensive, and can be applied flexibly across different populations. Thus, by validating oMEG for fetal recordings, FETAL-MIND offers an enormous technical contribution to both basic research and clinical fields. Furthermore, the project's findings may lay the groundwork for developing early biomarkers of atypical neurodevelopment, particularly for conditions involving social deficits such as autism spectrum disorder. The project is structured into five work packages (WPs). WP1 pilots the stimuli and estimates effect sizes. WP2 conducts larger-scale experiments based on results from WP1 and focuses on neural effects, while WP3 focuses on arousal effects (fetal heart rate). WP4 compares sMEG and oMEG recordings in the same fetal subjects and, finally, WP5 follows up with postnatal measurements. This staged approach mitigates risks by allowing for methodological refinement based on intermediate results from WP1. Moreover, FETAL-MIND leverages expertise and resources at the Tuebingen fMEG Center, including specialized equipment and established protocols for fetal MEG recordings to maximize success.

Keywords: fetus,infant,magnetoencephalography
Advancing genetic medicines for inherited kidney disease (RENALGENE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Prevention,  Diagnosis and T reatment of Human Diseases
Panel description: Medical technologies  and tools for prevention, diagnosis and treatment of human diseases, therapeutic approaches and interventions , pharmacology, preventative  medicine, epidemiology and public health , digital medicine
Countries involved: Spain
Call: ERC STARTING GRANTS (ERC-2025-STG, 2025)
Start date: 2026-02-01
End date: 2031-01-31
Duration (months): 60.0
Total project cost (EUR): 1500000.0
EU funding (EUR): 1500000.0
Participants: 1
Project status: SIGNED

Chronic kidney disease (CKD) is a leading cause of global mortality, affecting ~13% of global population. Inherited kidney diseases (IKD) are estimated to account for a 30% of CKD cases. Despite the unprecedented development of genetic medicines in the past decades, to date no kidney gene therapy intervention is available. Renal gene therapies have encountered two main barriers: (1) its complex anatomy and function has hampered efficient and specific delivery of genetic therapies to the kidney, and (2) many IKDs are caused by mutations in large genes, and therefore, traditional gene supplementation strategies using efficient and safe in vivo vectors (such as adeno-associated viral vectors or AAV) cannot be developed due to the limited packaging capacity. The main goal of this proposal is to create solutions for these challenges by developing novel gene therapy vectors with improved kidney targeting and genome editing strategies to correct the genetic defect in large genes that cause IKDs. Recent advances in the field of discovery and engineering of gene delivery vehicles combined with CRISPR-based gene editing technologies have opened the avenue towards developing efficient and safe gene editing therapies. In this proposal, we will develop in vivo genome editing approaches for Autosomal Dominant Polycystic Kidney Disease (ADPKD), the most frequent IKD with an incidence of 1:1,000. For this, we will develop novel AAV gene delivery vectors, a technology that has been clinically validated to target several tissues, enabling an efficient delivery of CRISPR editors to the kidney. Additionally, CRISPR approaches will be designed to restore the physiological expression of the mutated PKD1 gene that causes ADPKD and tested in APDKD mouse and pig models in vivo and in patient-derived kidney organoid models in vitro. The completion of this proposal will enable the generation of personalized and universally applicable in vivo gene editing therapies for ADPKD patients.

Keywords: inherited kidney disease,gene therapy,gene editing,viral vectors,organoids,in vivo disease models
SHORE: EmpOweR Students as the agents of cHangE (SHORE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Ocean, seas and waters
Destination: Ocean, seas and waters
Action type: Coordination and support actions
Countries involved: Türkiye,France,Romania,Italy,Austria,Hungary,Estonia,Ireland,Poland,Czechia,Denmark,Slovenia
Call: Student and school activities for the promotion of education on ‘blue’ sustainability and the protection of marine and freshwater ecosystems (HORIZON-MISS-2022-OCEAN-01, 2022)
Start date: 2023-08-01
End date: 2026-07-31
Duration (months): 36.0
Total project cost (EUR): 2998518.75
EU funding (EUR): 2998518.75
Participants: 22
Project status: SIGNED

SHORE will be focusing on engaging & mobilizing students, teachers, and schools to implement the Mission Ocean objectives to increase ocean literacy with the help of community activities & cooperation projects. SHORE project will last 36 months and cover five different regional areas (Baltic, Black, Mediterranean Sea, Danube & Rhine River Area) with its 14 consortium partners. It will set up Country Hubs to offer guidance for the educators and schools on Blue Curricula, develop and implement their projects and use open schooling methodologies. Contry Hubs will also promote community activities such as exhibitions, workshops, training, seminars, and meetNtalks to increase the awareness of ocean literacy among the society. SHORE will provide grants to 100 schools through three open call periods for proposals to support blue projects for a maximum amount of up to 10.000 euro per grant. Educational materials and trainings for educators will be available during th eprojec to increase their knowledge about sustainable and blue education. A digital platform will be set-up to monitor school projects, and provide a virtual learning environment system including rewards and badges. In addition, at the end of each school period, a public voting session will be held to raise awareness & engagement, create a wider audience and select the best school project which will receive the "Ocean Ambassador/Literate of the Year Award. An Ocean Literacy Action Center will be established within the YTU to coordinate public activities and bring researchers and public together to enhance ocean literacy during the project and thereafter.

Keywords: ocean literacy,education,environmental education,primary and secondary students,european network of blue schools,
Patient-centred, evidence-based late effect screening and follow-up care of survivors of adolescent and young adult cancer (PanCare4AYA)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Cancer
Destination: Cancer
Action type: Research and Innovation actions
Countries involved: Netherlands,Lithuania,Norway,United Kingdom,Germany,Italy,Belgium,Ireland,Croatia,Czechia,France,Sweden,Switzerland
Call: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer (HORIZON-MISS-2024-CANCER-01, 2024)
Start date: 2025-04-01
End date: 2030-03-31
Duration (months): 60.0
Total project cost (EUR): 5770234.25
EU funding (EUR): 5770234.25
Participants: 31
Project status: SIGNED

Survivors of AYA cancer are at risk of treatment-related mortality and morbidity (late effects). The impact on the quality of life (QoL) of AYA cancer survivors and their families, as well as the societal and economic burdens, is significant. However, these impacts can be prevented or reduced by long-term, systematic screening and follow-up (Survivorship Care), which enables the early detection of treatable late effects and timely interventions to preserve health, increase empowerment, manage chronic conditions and improve QoL. PanCare4AYA will improve Survivorship Care for AYA cancer survivors across Europe by developing an international clinical guideline for screening and follow-up. This guideline will be implemented via a novel person-centred screening programme (AYA Cancer Survivor Screen). An implementation study involving 1,000 AYA cancer survivors in 11 European countries (Croatia, Czech Republic, France, Germany, Italy, Lithuania, Netherlands, Norway, Sweden, Switzerland, United Kingdom) will be conducted to test the AYA Cancer Survivor Screen programme, including peer support. The study will look at effectiveness (empowerment, mental health, psychosocial functioning and other QoL-related outcomes), healthcare delivery and screening-related health, experiences of AYA cancer survivors and HCPs with implementing the state-of-the-art screening programme within a range of different healthcare settings, and feasibility. Innovative digital tools will be used in France, Italy, Lithuania and Netherlands. Ensuring the scalability of the AYA Cancer Survivor Screen programme is crucial for achieving enduring, real-world improvements to Survivorship Care for AYA cancer survivors. Therefore, the project includes the assessment of barriers and facilitators for the screening programme and development of freely available materials to support sustainable maintenance and scale-up of AYA Cancer Survivor Screen in additional clinics in future. This action is part of the Cancer Mission cluster of projects on “Quality of life (AYA)”.

Keywords: adolescent and young adult,cancer,screening,guidelines
CamoUflaged nanopaRticle-driven duAl Therapy to eradicate aggressIVe nEuroblastoma (CURATIVE)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2026-06-01
End date: 2028-05-31
Duration (months): 24.0
Total project cost (EUR): 194074.56
EU funding (EUR): 194074.56
Participants: 1
Project status: SIGNED

Neuroblastoma (NB) is a highly aggressive paediatric cancer, accounting for 15% of childhood cancer deaths. The 5-year survival rate for high-risk NB patients is less than 50%. Despite the significant advances in treatment options, the high tumour heterogeneity, drug resistance, and severe toxicities associated with conventional therapies continue to result in poor outcomes for high-risk NB patients. Recent studies showed that these challenges, along with frequent relapses, may be linked to the intrinsic resistance of a specific population of cells known as cancer stem cells (CSCs). CURATIVE aims to address this by developing a chitosan-based nanoparticle (NP) that co-encapsulates a systematically identified and optimized synergistic combination of drugs designed to target both CSCs and a key mechanism driving NB progression. The NP, which will enable controlled and sustained drug release, will be coated with plasma membranes derived from NB cells to enhance tumour targeting and accumulation through homotypic targeting. By leveraging the innovative use of NB cell membranes, the NP can closely mimic the tumour environment, allowing it to evade the immune system and preferentially accumulate at the tumour site. This approach enhances both specificity and efficacy, while simultaneously reducing off-target effects and minimizing systemic toxicity. The expected outcomes of CURATIVE include increased survival and treatment efficacy, reduced relapse rates and toxicity, and improved quality of life for paediatric patients. Overall, CURATIVE is positioned to provide valuable insights and resources to the scientific community, supporting the EU's objectives of advancing innovation in paediatric cancer care.

Keywords: neuroblastoma,nanomedicine,pediatric cancer therapy
Sustainable Bioinspired Wax Coating for Multi-Functional Crop Protection (SafeWax)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Israel,Italy,France,Germany
Call: EIC Pathfinder Open 2022 (HORIZON-EIC-2022-PATHFINDEROPEN-01, 2022)
Start date: 2023-03-01
End date: 2027-02-28
Duration (months): 48.0
Total project cost (EUR): 2868446.25
EU funding (EUR): 2868446.25
Participants: 6
Project status: SIGNED

According to the FAO, plant diseases cost the global economy around 210€ billion per year, and fungal pathogens destroy at least a third of all food crops annually. Commercial agriculture relies on chemical fungicides for crop protection owing to their easy application and low cost; however, their overuse and misuse have devastating implications for all living systems and the entire ecosystem. Thus, establishing sustainable crop protection strategies is essential for global economic development, environmental protection, and food security. Inspired by superhydrophobic plants, such as lotus and broccoli which exhibit wax crystals on their cuticles, we propose a generic sustainable strategy for passive crop protection against fungal pathogens. Our biomimetic technology, termed SafeWax, relies on bio-derived non-toxic fatty acid-based sprayable formulations which self-assemble into a multifaceted protective coating with anti-adhesive, self-cleaning and antifungal properties. When applied on sensitive crops, which do not naturally exhibit wax crystals, SafeWax will synthetically render their foliage to passively resist pathogens. SafeWax concepts will initially be demonstrated on grapevine, as a relevant model crop of high importance to Europe’s economy, environment and culture, which is highly susceptible to fungal diseases and is the most-frequently treated crop. SafeWax will then be expanded to other sensitive commodity crops. The biodegradable SafeWax coating will not only protect crops from fungal infections but will also be tuned to provide UV radiation filtering, prevent sun damage, as well as facilitate water collection from dew condensation, mitigating inevitable effects of climate change. SafeWax will revolutionize the global fungicides market (valued > 20 billion €), starting from the biofungicide market with a value of 3,2 billion € by 2025.

Keywords: fungicide,pesticide,wax,fatty acids,plant protection product,bioinspired
CarMen (CarMen)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Border Management
Action type: Research and Innovation actions
Countries involved: France,Greece,United Kingdom,Croatia,Switzerland,Germany
Call: Beyond the state-of-the-art “biometrics on the move” for border checks (HORIZON-CL3-2023-BM-01, 2023)
Start date: 2024-09-01
End date: 2027-08-31
Duration (months): 36.0
Total project cost (EUR): 3538688.67
EU funding (EUR): 2998347.88
Participants: 16
Project status: SIGNED

Challenges related to “on the move” biometrics are 1/ lower quality live biometric data, and 2/ no time to read the ePassport. Also, fully automatic biometric border control solutions, even with a stop allowed, are currently deployed only for pedestrians in controlled environments. Carmen innovates biometric solutions for non-stop border control, suitable for pedestrians and vehicles, in uncontrolled environmental conditions. Travellers’ authentication is achieved in two steps: 1) the biometric data (face, iris, periocular) of travellers is securely stored in their smartphones, thanks to a DTC (Digital Traveller Credential); 2) the biometric data is securely transferred from the DTC to the border authroity infrastructure, and compared to the live biometric data collected as the traveller crosses the border control point. To address a variety of environmental conditions, Carmen uses both NIR and RGB live biometric images and compares them to the reference images that have been acquired with one type of lighting only. To make biometrics more robust, Carmen has a multimodal approach on face iris and periocular regions. In fraud detection, Carmen detects presentation attacks on moving travellers and detects anomalous traveller behaviour. To address small and large border crossing points, Carmen enables the use of fix and body-worn cameras. To address travellers in cars or lorries, Carmen detects face images in slowly moving vehicles, through the windows. Travellers in coaches are controlled by border guards walking through the coach, using dedicated portable equipment as they walk. Carmen addresses the robustness of DTC via data injection attacks. Carmen complies with the existing legal and ethical standards, and privacy is a central concern. Carmen solutions will be demonstrated in operational conditions over the UK – France border, as French and UK border authorities are part of Carmen consortium, using the infrastructure proposed by the partner Brittany Ferries.
Personalised response monitoring in oncology: co-creating clinical trials in advanced breast cancer (PREMIO COLLAB)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Mission
Theme: Cancer
Destination: Cancer
Action type: Research and Innovation actions
Countries involved: Denmark,Germany,Austria,Switzerland,United Kingdom,Italy,Sweden
Call: Pragmatic clinical trials on minimally invasive diagnostics (HORIZON-MISS-2023-CANCER-01, 2023)
Start date: 2024-01-01
End date: 2029-12-31
Duration (months): 72.0
Total project cost (EUR): 7543676.25
EU funding (EUR): 7537801.25
Participants: 13
Project status: SIGNED

PREMIO COLLAB’s vision is to prolong overall survival and improve the quality of life for patients with metastatic breast cancer (MBC) by providing refined guidance for managing response monitoring. PREMIO COLLAB strives to facilitate improved patient care and streamlined clinical workflows addressing the needs of patients, healthcare professionals, and society. Response evaluation methods for patients with MBC have not been modernised for decades, although molecular imaging with FDG-PET/CT has emerged as a highly accurate method for staging MBC, and staging and monitoring MBC has a profound influence on treatment options and the chances of survival. Furthermore, the patient perspective has rarely been considered, although continuous response evaluation in a monitoring setting has interacted with the life of MBC patients for years. Still, no specific recommendations are provided internationally for response evaluation in MBC or in the overall management of monitoring. PREMIO COLLAB offers complementary competencies in an interdisciplinary collaborative effort to lift this complex task. In a pragmatic multicenter randomised clinical trial (RCT), we will apply the intervention of FDG-PET/CT-based monitoring and compare it with conventional CT as state-of-the-art. The objectives are to analyse the impact of the intervention on overall survival and quality of life in patients with MBC and include cost-effectiveness analyses directly informing HTA agencies and health policymakers. Building on knowledge from the RCT, we will use participatory research designs to develop improved and modernised patient pathways and digital workflows. AI-based solutions in imaging and liquid biopsies constitute perspectives with a broader horizon. The work will be done in multiple European centres and living labs with patient representatives, clinicians, and relevant stakeholders aiming to provide knowledge for updated recommendations with a view to subsequent clinical implementation. This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”

Keywords: pragmatic trials,fdg pet ct,metastatic breast cancer,response evaluation,monitoring
A New Measure of Socioeconomic Inequalities for International Comparison (INCASI2)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Staff Exchanges
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Spain,Italy,France,Finland,Netherlands,Chile,Argentina,Cuba,Bolivia, Plurinational State of,Uruguay,Brazil,Mexico,United States,United Kingdom
Call: MSCA Staff Exchanges 2022 (HORIZON-MSCA-2022-SE-01, 2022)
Start date: 2023-11-01
End date: 2027-10-31
Duration (months): 48.0
Total project cost (EUR): 1614600.0
EU funding (EUR): 1614600.0
Participants: 30
Project status: SIGNED

The overall objective of the INCASI2 project is to establish a global cross-sectoral network of experts working on a joint research programme aimed at building a new analytical model of socioeconomic inequalities in order to: a) To produce effective advances in the understanding of the complex phenomena of socioeconomic inequalities creating a fresh analytical framework at a comparative and interdisciplinary level in a context of societies in "permanent crisis". b) To construct an innovative multidimensional measure (DYSIC: Dynamics of Socioeconomic Inequality in Comparison) adapted to the new realities shaped in this context that is global, more comprehensive and realistic in the comparative analysis of inequalities between Europe and Latin America & the Caribbean, and to monitor the situation and evolution of inequalities. We consider 3 DYSIC variants: 1) including 3 main dimensions as a base (education, occupation and income), 2) adding gender dimension and 3) adding dynamic trends. c) To create the INCASI Living Lab to elaborate diagnoses, contribute to informed decision-making and the design of public policies. It is designed to enhance the innovation process by embracing three core principles: fostering a collaborative open innovation strategy, utilizing a methodology centred on promoting the quality of life for individuals, and creating an environment for interdisciplinary thinking and action that enables the participation of diverse socioeconomic, political, and scientific agents. These objectives will be achieved with a collaborative work of an interdisciplinary, intersectoral and international network for Comparative Analysis of Socioeconomic Inequalities (INCASI) with 29 organizations: 14 EU universities from 6 countries, 11 universities and 4 non-academic organizations from 7 LAC countries and the USA, in order to face one of the most relevant problem in our societies: socioeconomic inequalities, and promote European values of social justice.

Keywords: gender,migration,latin america and caribbean,comparative analysis,dynamic analysis,development